|
22 Companies |
|
18 Products |
|
18 Products |
|
0 Mechanisms of Action |
|
0 Trials |
|
151 News |
|
| 123» |
- | Nebido (testosterone undecanoate depot injection) / Bayer
Trial completion date, Trial primary completion date: ALCeP: Androgen for Leydig Cell Proliferation (clinicaltrials.gov) - Sep 26, 2018
P2/3, N=56, Completed, Sponsor: University of Roma La Sapienza
Trial completion date: Oct 2014 --> Jun 2018 | Trial primary completion date: Aug 2013 --> Jun 2017
- | Growtropin-II (somatropin biosimilar) - Dong / A
Trial completion: A Clinical Study to Assess the Efficacy and Safety of DA-3002 (clinicaltrials.gov) - Jul 27, 2018
P3, N=58, Completed, Sponsor: Dong-A ST Co., Ltd.
Trial completion date: Oct 2014 --> Jun 2018 | Trial primary completion date: Aug 2013 --> Jun 2017 Active, not recruiting --> Completed
- |||| Growtropin-II (somatropin biosimilar) - Dong / A
Trial primary completion date: A Clinical Study to Assess the Efficacy and Safety of DA-3002 (clinicaltrials.gov) - Sep 20, 2017
P3, N=58, Active, not recruiting, Sponsor: Dong-A ST Co., Ltd.
Active, not recruiting --> Completed Trial primary completion date: Jun 2016 --> May 2018
- | Trial completion, Trial primary completion date: Risk of Diabetes in Young Turner Syndrome Patients (clinicaltrials.gov) - Aug 23, 2017
P=N/A, N=120, Completed, Sponsor: Children's Hospital Medical Center, Cincinnati
Trial primary completion date: Jun 2016 --> May 2018 Recruiting --> Completed | Trial primary completion date: Dec 2015 --> Jun 2017
- | Trial completion: The Effects of Hormones in Growth Hormone-Treated Girls With Turner Syndrome (clinicaltrials.gov) - Jun 30, 2017
P2, N=80, Completed, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting --> Completed | Trial primary completion date: Dec 2015 --> Jun 2017 No longer recruiting --> Completed
- ||| Trial completion, Enrollment change: Memantine Treatment in Fragile X-Associated Tremor/Ataxia Syndrome (clinicaltrials.gov) - May 30, 2017
P=N/A, N=94, Completed, Sponsor: University of California, Davis
No longer recruiting --> Completed Recruiting --> Completed | N=180 --> 94
- | Trial completion, Enrollment change, Trial primary completion date: Micro RNAs as a Marker of Aortic Aneurysm in Hereditary Aortopathy Syndromes (clinicaltrials.gov) - Mar 15, 2017
P=N/A, N=20, Completed, Sponsor: University of Colorado, Denver
Recruiting --> Completed | N=180 --> 94 Recruiting --> Completed | N=100 --> 20 | Trial primary completion date: Oct 2016 --> Jul 2016
- ||| Norditropin (somatropin) / Novo Nordisk
Trial completion, Enrollment change: Observational Prospective Study on Patients Treated With Norditropin® (clinicaltrials.gov) - Feb 6, 2017
P=N/A, N=21249, Completed, Sponsor: Novo Nordisk A/S
Recruiting --> Completed | N=100 --> 20 | Trial primary completion date: Oct 2016 --> Jul 2016 Enrolling by invitation --> Completed | N=17000 --> 21249
- Trial completion, Enrollment change, Trial primary completion date: FPEB: A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions (clinicaltrials.gov) - Jan 6, 2017
P1, N=48, Completed, Sponsor: Institute for Neurodegenerative Disorders
Enrolling by invitation --> Completed | N=17000 --> 21249 Recruiting --> Completed | N=155 --> 48 | Trial primary completion date: Dec 2015 --> Oct 2016
- Trial completion: GenTAC: National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions (clinicaltrials.gov) - Dec 20, 2016
P=N/A, N=3706, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting --> Completed | N=155 --> 48 | Trial primary completion date: Dec 2015 --> Oct 2016 Active, not recruiting --> Completed
- Trial completion, Enrollment change: Subcapsular Orchiectomy in Men With Klinefelter Syndrome (clinicaltrials.gov) - Oct 4, 2016
P=N/A, N=14, Completed, Sponsor: Odense University Hospital
Active, not recruiting --> Completed Recruiting --> Completed | N=20 --> 14
- Trial completion, Enrollment change, Trial primary completion date: Pregnancy Chances in Classic Galactosemia (clinicaltrials.gov) - Sep 13, 2016
P=N/A, N=85, Completed, Sponsor: Maastricht University Medical Center
Recruiting --> Completed | N=20 --> 14 Recruiting --> Completed | N=150 --> 85 | Trial primary completion date: Dec 2015 --> Sep 2016
- Trial primary completion date: Micro RNAs as a Marker of Aortic Aneurysm in Hereditary Aortopathy Syndromes (clinicaltrials.gov) - Aug 22, 2016
P=N/A, N=100, Recruiting, Sponsor: University of Colorado, Denver
Recruiting --> Completed | N=150 --> 85 | Trial primary completion date: Dec 2015 --> Sep 2016 Trial primary completion date: Jun 2016 --> Oct 2016
- |||| metadoxine extended-release (MG01CI) / Arcturus Therap
Trial completion: A 6-week, Study of MG01CI Low Dose and High Dose Compared With Placebo in Adults and Adolescents With Fragile X Syndrome (clinicaltrials.gov) - Jul 7, 2016
P2, N=62, Completed, Sponsor: Alcobra Ltd.
Trial primary completion date: Jun 2016 --> Oct 2016 Active, not recruiting --> Completed
- Trial primary completion date: Micro RNAs as a Marker of Aortic Aneurysm in Hereditary Aortopathy Syndromes (clinicaltrials.gov) - Jun 2, 2016
P=N/A, N=100, Recruiting, Sponsor: University of Colorado, Denver
Active, not recruiting --> Completed Trial primary completion date: Mar 2016 --> Jun 2016
- Trial completion, Enrollment change, Trial primary completion date: Aortopathy in Persons With Bicuspid Aortic Valve, Turner and Marfan Syndrome (clinicaltrials.gov) - May 25, 2016
P=N/A, N=5, Completed, Sponsor: University of Aarhus
Trial primary completion date: Mar 2016 --> Jun 2016 Recruiting --> Completed | N=60 --> 5 | Trial primary completion date: Oct 2016 --> Oct 2015
- Trial completion, Enrollment change: X-chromosome Inactivation, Epigenetics and the Transcriptome (clinicaltrials.gov) - May 25, 2016
P=N/A, N=110, Completed, Sponsor: University of Aarhus
Recruiting --> Completed | N=60 --> 5 | Trial primary completion date: Oct 2016 --> Oct 2015 Active, not recruiting --> Completed | N=395 --> 110
- Trial completion, Trial primary completion date: Genetic Etiology in Premature Ovarian Insufficiency (clinicaltrials.gov) - Apr 18, 2016
P=N/A, N=100, Completed, Sponsor: BEGUM AYDOGAN
Active, not recruiting --> Completed | N=395 --> 110 Recruiting --> Completed | Trial primary completion date: Nov 2015 --> Apr 2016
- Biomarker, Trial completion, Enrollment change: Brain Connectivity in Neurodevelopmental Disorders in Response to Treatment (clinicaltrials.gov) - Apr 18, 2016
P=N/A, N=25, Completed, Sponsor: University of North Carolina, Chapel Hill
Recruiting --> Completed | Trial primary completion date: Nov 2015 --> Apr 2016 Enrolling by invitation --> Completed | N=60 --> 25
- Enrollment change, Trial termination: EXPLAIN -FragilE X Registry: An exPlorative Longitudinal Study for chAracterIzation, Treatment Pathways and patieNt-related Outcomes (clinicaltrials.gov) - Mar 5, 2016
P=N/A, N=75, Terminated, Sponsor: Novartis Pharmaceuticals
Enrolling by invitation --> Completed | N=60 --> 25 N=300 --> 75 | Recruiting --> Terminated
- minocycline extended release / Generic mfg.
Trial completion, Trial initiation date, Trial primary completion date: Add-on Pilot Trial of Minocycline to Treat Fragile X Syndrome (clinicaltrials.gov) - Feb 19, 2016
P=N/A, N=20, Completed, Sponsor: FRAXA Research Foundation
N=300 --> 75 | Recruiting --> Terminated Active, not recruiting --> Completed | Initiation date: Jan 2009 --> Oct 2007 | Trial primary completion date: Nov 2009 --> Nov 2008
- sertraline / Generic mfg.
Trial completion: Trial of Sertraline to Treat Children With Fragile X Syndrome (clinicaltrials.gov) - Jan 28, 2016
P2, N=57, Completed, Sponsor: University of California, Davis
Active, not recruiting --> Completed | Initiation date: Jan 2009 --> Oct 2007 | Trial primary completion date: Nov 2009 --> Nov 2008 Active, not recruiting --> Completed
- Trial primary completion date: Micro RNAs as a Marker of Aortic Aneurysm in Hereditary Aortopathy Syndromes (clinicaltrials.gov) - Jan 18, 2016
P=N/A, N=100, Recruiting, Sponsor: University of Colorado, Denver
Active, not recruiting --> Completed Trial primary completion date: Nov 2015 --> Mar 2016
- ||| Trial completion: Prenatal Screening for Down Syndrome With DNAFirst (clinicaltrials.gov) - Dec 23, 2015
P=N/A, N=100, Completed, Sponsor: Women and Infants Hospital of Rhode Island
Trial primary completion date: Nov 2015 --> Mar 2016 Active, not recruiting --> Completed
- |||| trofinetide (NNZ-2566) / Neuren, Acadia Pharma
Trial completion: A Safety Study of NNZ-2566 in Patients With Fragile X Syndrome (clinicaltrials.gov) - Oct 31, 2015
P2, N=72, Completed, Sponsor: Neuren Pharmaceuticals Limited
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| somatropin / Generic mfg.
Trial completion: GeNeSIS: Observational Study of Somatropin Treatment in Children (clinicaltrials.gov) - Oct 27, 2015
P=N/A, N=22929, Completed, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial primary completion date: Risk of Diabetes in Young Turner Syndrome Patients (clinicaltrials.gov) - Sep 28, 2015
P=N/A, N=120, Recruiting, Sponsor: Children's Hospital Medical Center, Cincinnati
Active, not recruiting --> Completed Trial primary completion date: Sep 2015 --> Dec 2015
- |||| somatropin / Generic mfg.
Trial completion, Enrollment change: Long-Term Growth and Skeletal Effects of Early Growth Hormone Treatment in Turner Syndrome (clinicaltrials.gov) - Sep 26, 2015
P4, N=69, Completed, Sponsor: Eli Lilly and Company
Trial primary completion date: Sep 2015 --> Dec 2015 Recruiting --> Completed | N=88 --> 69
- Enrollment change, Trial termination, Trial primary completion date: Clinical Performance of the MaterniT21 PLUS LDT in Multiple Gestation Pregnancies (clinicaltrials.gov) - Sep 17, 2015
P=N/A, N=50, Terminated, Sponsor: Sequenom, Inc.
Recruiting --> Completed | N=88 --> 69 N=1000 --> 50 | Recruiting --> Terminated | Trial primary completion date: Feb 2015 --> Sep 2015; Slow enrollment of eligible subjects
- Trial primary completion date: Micro RNAs as a Marker of Aortic Aneurysm in Hereditary Aortopathy Syndromes (clinicaltrials.gov) - Aug 22, 2015
P=N/A, N=100, Recruiting, Sponsor: University of Colorado, Denver
N=1000 --> 50 | Recruiting --> Terminated | Trial primary completion date: Feb 2015 --> Sep 2015; Slow enrollment of eligible subjects Trial primary completion date: Jul 2015 --> Nov 2015
- ||| trofinetide (NNZ-2566) / Neuren, Acadia Pharma
Enrollment closed, Enrollment change: A Safety Study of NNZ-2566 in Patients With Fragile X Syndrome (clinicaltrials.gov) - Aug 17, 2015
P2, N=72, Active, not recruiting, Sponsor: Neuren Pharmaceuticals Limited
Trial primary completion date: Jul 2015 --> Nov 2015 Recruiting --> Active, not recruiting | N=60 --> 72
- sertraline / Generic mfg.
Enrollment closed, Phase classification, Enrollment change, Trial primary completion date: Trial of Sertraline to Treat Children With Fragile X Syndrome (clinicaltrials.gov) - Aug 15, 2015
P2, N=57, Active, not recruiting, Sponsor: University of California, Davis
Recruiting --> Active, not recruiting | N=60 --> 72 Recruiting --> Active, not recruiting | Phase classification: PN/A --> P2 | N=72 --> 57 | Trial primary completion date: Jul 2014 --> Aug 2015
- || Enrollment closed, Trial primary completion date: Prenatal Screening for Down Syndrome With DNAFirst (clinicaltrials.gov) - Jul 17, 2015
P=N/A, N=100, Active, not recruiting, Sponsor: Women and Infants Hospital of Rhode Island
Recruiting --> Active, not recruiting | Phase classification: PN/A --> P2 | N=72 --> 57 | Trial primary completion date: Jul 2014 --> Aug 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Jul 2015
- Norditropin (somatropin) / Novo Nordisk
Trial completion: Non-interventional Study of Patients Using Norditropin® for Growth Hormone Deficiency or Turner Syndrome (clinicaltrials.gov) - Jul 6, 2015
P=N/A, N=2016, Completed, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Jul 2015 Active, not recruiting --> Completed
- || Enrollment closed, Trial primary completion date: X-chromosome Inactivation, Epigenetics and the Transcriptome (clinicaltrials.gov) - Jun 29, 2015
P=N/A, N=395, Active, not recruiting, Sponsor: University of Aarhus
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2015 --> Oct 2015
- Trial primary completion date: Genetic Etiology in Premature Ovarian Insufficiency (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=100, Recruiting, Sponsor: BEGUM AYDOGAN
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2015 --> Oct 2015 Trial primary completion date: Jan 2015 --> Nov 2015
- Trial primary completion date: FPEB: A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions (clinicaltrials.gov) - Jun 11, 2015
P1, N=155, Recruiting, Sponsor: Institute for Neurodegenerative Disorders
Trial primary completion date: Jan 2015 --> Nov 2015 Trial primary completion date: Dec 2014 --> Dec 2015
- ||| Trial completion, Enrollment change: Life Quality and Health in Patients With Klinefelter Syndrome (clinicaltrials.gov) - Jun 3, 2015
P=N/A, N=452, Completed, Sponsor: University of Aarhus
Trial primary completion date: Dec 2014 --> Dec 2015 Enrolling by invitation --> Completed | N=1350 --> 452
- ||| Trial completion, Enrollment change: Neuropsychologic, Neuroradiologic, Endocrinologic, and Genetic Aspects of Klinefelter Syndrome (clinicaltrials.gov) - Jun 3, 2015
P=N/A, N=146, Completed, Sponsor: University of Aarhus
Enrolling by invitation --> Completed | N=1350 --> 452 Active, not recruiting --> Completed | N=450 --> 146
- Enrollment open: Micro RNAs as a Marker of Aortic Aneurysm in Hereditary Aortopathy Syndromes (clinicaltrials.gov) - May 28, 2015
P=N/A, N=100, Recruiting, Sponsor: University of Colorado, Denver
Active, not recruiting --> Completed | N=450 --> 146 Not yet recruiting --> Recruiting
- || Trial primary completion date: EXPLAIN -FragilE X Registry: An exPlorative Longitudinal Study for chAracterIzation, Treatment Pathways and patieNt-related Outcomes (clinicaltrials.gov) - Apr 19, 2015
P=N/A, N=300, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Trial primary completion date: Feb 2015 --> Dec 2015
- Norditropin (somatropin) / Novo Nordisk
Enrollment closed: Non-interventional Study of Patients Using Norditropin® for Growth Hormone Deficiency or Turner Syndrome (clinicaltrials.gov) - Apr 15, 2015
P=N/A, N=2000, Active, not recruiting, Sponsor: Novo Nordisk A/S
Trial primary completion date: Feb 2015 --> Dec 2015 Enrolling by invitation --> Active, not recruiting
- Trial completion, Trial primary completion date: Safety and Efficacy Study of Antioxidants for the Treatment of the Fragile X Syndrome (clinicaltrials.gov) - Apr 14, 2015
P2, N=30, Completed, Sponsor: Yolanda de Diego Otero
Enrolling by invitation --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Mar 2011 --> Apr 2015
- ||| metadoxine extended-release (MG01CI) / Arcturus Therap
Enrollment closed: A 6-week, Study of MG01CI Low Dose and High Dose Compared With Placebo in Adults and Adolescents With Fragile X Syndrome (clinicaltrials.gov) - Mar 27, 2015
P2, N=60, Active, not recruiting, Sponsor: Alcobra Ltd.
Active, not recruiting --> Completed | Trial primary completion date: Mar 2011 --> Apr 2015 Recruiting --> Active, not recruiting
- || trofinetide (NNZ-2566) / Neuren, Acadia Pharma
Trial primary completion date: A Safety Study of NNZ-2566 in Patients With Fragile X Syndrome (clinicaltrials.gov) - Feb 19, 2015
P2, N=60, Recruiting, Sponsor: Neuren Pharmaceuticals Limited
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2015 --> Sep 2015
- || trofinetide (NNZ-2566) / Neuren, Acadia Pharma
Trial primary completion date: A Safety Study of NNZ-2566 in Patients With Fragile X Syndrome (clinicaltrials.gov) - Feb 13, 2015
P2, N=60, Recruiting, Sponsor: Neuren Pharmaceuticals Limited
Trial primary completion date: Jun 2015 --> Sep 2015 Trial primary completion date: Dec 2014 --> Jun 2015
- |||| mavoglurant (AFQ056) / Novartis
Trial completion: Long-term, Safety, Tolerability and Efficacy Study of AFQ056 in Adult Patients With Fragile X Syndrome (clinicaltrials.gov) - Feb 13, 2015
P2, N=148, Completed, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Dec 2014 --> Jun 2015 Terminated --> Completed
- mavoglurant (AFQ056) / Novartis
Enrollment change, Trial termination: Long-term, Safety and Tolerability Study of AFQ056 in Adolescent Patients With Fragile X Syndrome (Open-label) (clinicaltrials.gov) - Dec 9, 2014
P2/3, N=10, Terminated, Sponsor: Novartis Pharmaceuticals
Terminated --> Completed N=170 --> 10 | Recruiting --> Terminated; The study treatment failed to demonstrate efficacy in target population in two other clinical studies (CAFQ056B2214 and CAFQ056A2212).
- | mavoglurant (AFQ056) / Novartis
Enrollment change, Trial termination: Long-term, Safety, Tolerability and Efficacy Study of AFQ056 in Adult Patients With Fragile X Syndrome (clinicaltrials.gov) - Dec 9, 2014
P2, N=148, Terminated, Sponsor: Novartis Pharmaceuticals
N=170 --> 10 | Recruiting --> Terminated; The study treatment failed to demonstrate efficacy in target population in two other clinical studies (CAFQ056B2214 and CAFQ056A2212). N=200 --> 148 | Recruiting --> Terminated; Study treatment AFQ056 failed to demonstrate efficacy in the adult patient with Fragile X Syndrome in 2 other clinical studies (CAFQ056B2214 and CAFQ056A2212)
- || Trial primary completion date: Aortopathy in Persons With Bicuspid Aortic Valve, Turner and Marfan Syndrome (clinicaltrials.gov) - Dec 7, 2014
P=N/A, N=60, Recruiting, Sponsor: University of Aarhus
N=200 --> 148 | Recruiting --> Terminated; Study treatment AFQ056 failed to demonstrate efficacy in the adult patient with Fragile X Syndrome in 2 other clinical studies (CAFQ056B2214 and CAFQ056A2212) Trial primary completion date: Oct 2014 --> Oct 2016